Zydus Lifesciences Ltd.

Cadila Healthcare has finalized definitive agreement with Microbix regarding re-launch of Urokinase, a critical care therapy in North America. The company, earlier on January 6, 2012, had reached the agreement with Microbix to market Urokinase.

Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.